Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	24.67B
Revenue (ttm)	11.58B
Net Income (ttm)	570.05M
Shares Out	231.00M
EPS (ttm)	2.47
PE Ratio	43.28
Forward PE	n/a
Dividend	2.10 (1.97%)
Ex-Dividend Date	Nov 17, 2025

Volume	217,258
Average Volume	168,494
Open	107.20
Previous Close	107.80
Day's Range	106.00 - 108.40
52-Week Range	92.40 - 147.50
Beta	-0.54
RSI	47.18
Earnings Date	Nov 30, 2025

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,162
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2024, Beacon Pharmaceuticals's revenue was 10.70 billion, an increase of 25.76% compared to the previous year's 8.51 billion. Earnings were 521.01 million, an increase of 2.19%.